Irene T.M. Lindenburg

Publicaties

Een proefschrift, 19 artikelen in internationale en Nederlandse tijdschriften (6 als eerste auteur) en 7 congresabstracts.

pubmed·europe pmc·alle referenties (ris)

Proefschrift

  1. 2015

    Intrauterine blood transfusion: indications, risks, quality control and long-term outcome

    Proefschrift, Universiteit Leiden, 10 september 2015

    promotor D. Oepkes·repository

Artikelen

  1. 2025

    Arbeidsgerichte zorg

    Ned Tijdschr Geneeskd 2025;169:D8629

    Lindenburg ITM, Boonen AERCH, Fakkert IE, van Zelm V, de Kock KA

    eerste auteur·ntvg.nl·pubmed

  2. 2018

    Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management

    Am J Obstet Gynecol 2018;219(4):393.e1-393.e8

    Slootweg YM, Lindenburg IT, Koelewijn JM, Van Kamp IL, Oepkes D, De Haas M

    medeauteur, auteur 2 van 6·doi·pubmed

  3. 2017

    Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures

    Ultrasound Obstet Gynecol 2017;50(2):180-186

    Zwiers C, Lindenburg ITM, Klumper FJ, de Haas M, Oepkes D, Van Kamp IL

    medeauteur, auteur 2 van 6·doi·pubmed

  4. 2016

    Immunoglobulins in neonates with rhesus hemolytic disease of the fetus and newborn: long-term outcome in a randomized trial

    Fetal Diagn Ther 2016;39(3):209-213

    van Klink JM, van Veen SJ, Smits-Wintjens VE, Lindenburg IT, Rijken M, Oepkes D, Lopriore E

    medeauteur, auteur 4 van 7·doi·pubmed

  5. 2015

    Health-related quality of life and behavioral functioning after intrauterine transfusion for alloimmune anemia

    J Pediatr 2015;167(5):1130-1135.e2

    van Klink JM, Lindenburg IT, Inklaar MJ, Verduin E, Koopman HM, van Kamp IL, Schonewille H, Oepkes D, Lopriore E, LOTUS Study Group

    medeauteur, auteur 2 van 10·doi·pubmed

  6. 2014

    Intrauterine blood transfusion: current indications and associated risks

    Fetal Diagn Ther 2014;36(4):263-271

    Lindenburg IT, van Kamp IL, Oepkes D

    eerste auteur·doi·pubmed

  7. 2013

    Long-term neurodevelopmental and cardiovascular outcome after intrauterine transfusions for fetal anaemia: a review

    Prenat Diagn 2013;33(9):815-822

    Lindenburg IT, van Klink JM, Smits-Wintjens VE, van Kamp IL, Oepkes D, Lopriore E

    eerste auteur·doi·pubmed

  8. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation

    BJOG 2013;120(7):847-852

    Lindenburg IT, van Kamp IL, van Zwet EW, Middeldorp JM, Klumper FJ, Oepkes D

    eerste auteur·doi·pubmed

  9. Postnatal outcome in neonates with severe rhesus c compared to rhesus D hemolytic disease

    Transfusion 2013;53(7):1580-1585

    Rath ME, Smits-Wintjens VE, Lindenburg IT, Folman CC, Brand A, van Kamp IL, Oepkes D, Walther FJ, Lopriore E

    medeauteur, auteur 3 van 9·doi·pubmed

  10. High anti-HLA response in women exposed to intrauterine transfusions for severe alloimmune hemolytic disease is associated with mother-child HLA triplet mismatches, high anti-D titer, and new red blood cell antibody formation

    Transfusion 2013;53(5):939-947

    Verduin EP, Schonewille H, Brand A, Haasnoot GW, Claas FH, Lindenburg IT, Lopriore E, Oepkes D, Roelen DL, Doxiadis II

    medeauteur, auteur 6 van 10·doi·pubmed

  11. 2012

    Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study

    Am J Obstet Gynecol 2012;206(2):141.e1-141.e8

    Lindenburg IT, Smits-Wintjens VE, van Klink JM, Verduin E, van Kamp IL, Walther FJ, Schonewille H, Doxiadis II, Kanhai HH, van Lith JM, van Zwet EW, Oepkes D, Brand A, Lopriore E, LOTUS Study Group

    eerste auteur·doi·pubmed

  12. Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome

    Am J Obstet Gynecol 2012;206(3):204.e1-204.e5

    De Jong EP, Lindenburg IT, van Klink JM, Oepkes D, van Kamp IL, Walther FJ, Lopriore E

    medeauteur, auteur 2 van 7·doi·pubmed

  13. Cholestasis in neonates with red cell alloimmune hemolytic disease: incidence, risk factors and outcome

    Neonatology 2012;101(4):306-310

    Smits-Wintjens VE, Rath ME, Lindenburg IT, Oepkes D, van Zwet EW, Walther FJ, Lopriore E

    medeauteur, auteur 3 van 7·doi·pubmed

  14. 2011

    Quality control for intravascular intrauterine transfusion using cumulative sum (CUSUM) analysis for the monitoring of individual performance

    Fetal Diagn Ther 2011;29(4):307-314

    Lindenburg IT, Wolterbeek R, Oepkes D, Klumper FJ, Vandenbussche FP, van Kamp IL

    eerste auteur·doi·pubmed

  15. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial

    Pediatrics 2011;127(4):680-686

    Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, Oepkes D, Brand A, Lopriore E

    medeauteur, auteur 4 van 9·doi·pubmed

  16. Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease

    Vox Sang 2011;100(3):312-316

    Rath ME, Smits-Wintjens VE, Lindenburg IT, Brand A, van Kamp IL, Oepkes D, Walther FJ, Lopriore E

    medeauteur, auteur 3 van 8·doi·pubmed

  17. 2010

    Long-term follow up after intra-uterine transfusions; the LOTUS study

    BMC Pregnancy Childbirth 2010;10:77

    Verduin EP, Lindenburg IT, Smits-Wintjens VE, van Klink JM, Schonewille H, van Kamp IL, Oepkes D, Walther FJ, Kanhai HH, Doxiadis II, Lopriore E, Brand A

    medeauteur, auteur 2 van 12·doi·pubmed

  18. Top-up transfusions in neonates with Rh hemolytic disease in relation to exchange transfusions

    Vox Sang 2010;99(1):65-70

    Rath ME, Smits-Wintjens VE, Lindenburg I, Brand A, Oepkes D, Walther FJ, Lopriore E

    medeauteur, auteur 3 van 7·doi·pubmed

  19. 2008

    Implementation of routine screening for Kell antibodies: does it improve perinatal survival?

    Transfusion 2008;48(5):953-957

    Kamphuis MM, Lindenburg I, van Kamp IL, Meerman RH, Kanhai HH, Oepkes D

    medeauteur, auteur 2 van 6·doi·pubmed

Congresabstracts

  1. 2013

    Health-related quality of life and behavioral outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn

    Am J Obstet Gynecol. 2013;208(1 Suppl):S183-S184, abstract 419

    eerste auteur·doi

  2. 2012

    Long-term neurodevelopment in children after intrauterine transfusion for parvovirus B19 infection

    Am J Obstet Gynecol. 2012;206(1 Suppl):S22-S23, abstract 35

    medeauteur·doi

  3. No protective effect of NIMA on antibody production in women transfused for severe hemolytic disease of the fetus

    J Reprod Immunol. 2012;94(1):15

    medeauteur·doi

  4. 2011

    Long term follow-up after intra-uterine transfusions: the LOTUS study

    Am J Obstet Gynecol. 2011;204(1 Suppl):S32, abstract 54

    eerste auteur·doi

  5. Increased risk of intravascular intrauterine transfusion before 20 weeks gestation in the treatment of severe red cell alloimmunization

    Am J Obstet Gynecol. 2011;204(1 Suppl):S166-S167, abstract 412

    eerste auteur·doi

  6. Fetal microchimerism may play a role in persistent fetal induced RBC antibody formation

    J Reprod Immunol. 2011;90(2):136-137

    medeauteur·doi

  7. 2010

    Fetal induced red blood cell antibodies persist over 20 years

    J Reprod Immunol. 2010;86(2):109

    medeauteur·doi

Bron: Europe PMC en Crossref, 7 oktober 2026. Oudere artikelen staan onder Lindenburg IT of Lindenburg I.